US8740602052
US8740602052
Takeda Pharmaceutical Company L
Loading chart...
Solid Quality Asset with Moderate Fluctuation
Healthy balance: Exemplary business financials (Health Score: 60/100) paired with moderate price swings for a single equity (±19.3% p.a.). The score (5/7) reflects the standard baseline for equities under SRI rules.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
5/7 Elevated
5 / 7 SRI Price Fluctuation & Beta
Above-average volatility. Suitable for experienced investors with high risk tolerance (5+ years horizon). Moves noticeably less than the broader market (0.1x).
Beta (Market Relation)
0.1x
DefensiveVolatility (5Y p.a.)
19.3% p.a.
5-Year HorizonMax Drawdown (5Y)
-26.4%
5-Year HorizonSharpe Ratio
0.15
Return / RiskElevated Risk / Growth: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +29.4% |
| 3 Years | 19.9% | -20.1% | 0.21 | +6.7% |
| 5 Years | 19.3% | -26.4% | 0.15 | +5.4% |
| 10 Years | 23.1% | -59.6% | -0.21 | -2.5% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Historical Stress Test: Maximum peak-to-trough drawdown of -59.6% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
-
Audit Risk
-
Board Risk
-
Short Ratio
1.92